{
  "id": 18012287,
  "title": "Rhythm expects to dose first Phase III bivamelagon HO patients in January as it commits to $350M royalty buy-down",
  "url": "https://urgent.news/2026/11/03/rhythm-expects-to-dose-first-phase-iii-bivamelagon-ho-patients-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T19:57:14.000Z",
  "source": {
    "name": "Seeking Alpha News",
    "slug": "seeking-alpha-news",
    "url": "https://seekingalpha.com/news/4663973-rhythm-expects-to-dose-first-phase-iii-bivamelagon-ho-patients-in-january-as-it-commits-to?feed_item_type=news"
  },
  "original_language": "en",
  "account": null,
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}